Biohaven Stock Price, News & Analysis (NYSE:BHVN) $33.32 -0.18 (-0.54%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$32.96▼$34.1550-Day Range$22.96▼$33.9652-Week Range$12.35▼$34.21Volume672,334 shsAverage Volume1.05 million shsMarket Capitalization$2.67 billionP/E RatioN/ADividend YieldN/APrice Target$29.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Biohaven MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside12.3% Downside$29.17 Price TargetShort InterestHealthy10.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.09Based on 3 Articles This WeekInsider TradingAcquiring Shares$3.40 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.23) to ($5.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector788th out of 949 stocksPharmaceutical Preparations Industry348th out of 408 stocks 1.5 Analyst's Opinion Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.17, Biohaven has a forecasted downside of 12.3% from its current price of $33.25.Amount of Analyst CoverageBiohaven has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.49% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Biohaven has recently decreased by 8.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BHVN. Previous Next 2.8 News and Social Media Coverage News SentimentBiohaven has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biohaven this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,402,138.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.50% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.60% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($5.23) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biohaven Stock (NYSE:BHVN)Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.Read More BHVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHVN Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comBiohaven (NYSE:BHVN) Trading Down 2.6%December 1, 2023 | finance.yahoo.comBiohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingDecember 6, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. November 29, 2023 | markets.businessinsider.comBuy Rating for Biohaven Ltd. on Strong BHV-7000 Prospects in MDD and Epilepsy MarketsNovember 27, 2023 | msn.comBiohaven (BHVN) Price Target Increased by 19.39% to 34.34November 22, 2023 | finance.yahoo.comWill Biohaven (NYSE:BHVN) Spend Its Cash Wisely?November 21, 2023 | markets.businessinsider.comBuy Rating for Biohaven Ltd.: Promising Developments in BHV-1300 and BHV-7000 Programs and Potential Offset of Operating ExpensesNovember 15, 2023 | finance.yahoo.comBiohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ...December 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 14, 2023 | nl.investing.comBiohaven Pharma winst lager dan voorspeld, omzet volgens verwachtingNovember 14, 2023 | finance.yahoo.comBiohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsNovember 6, 2023 | finance.yahoo.comBiohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's WhyOctober 31, 2023 | finance.yahoo.comAre Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?October 31, 2023 | finance.yahoo.comAre Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?October 19, 2023 | finance.yahoo.comHere's Why Momentum in Biohaven Ltd. (BHVN) Should Keep goingOctober 16, 2023 | finance.yahoo.comBiohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®October 12, 2023 | finance.yahoo.comBiohaven Independent Director Acquires 8.0% More StockOctober 9, 2023 | finance.yahoo.comWith 73% ownership of the shares, Biohaven Ltd. (NYSE:BHVN) is heavily dominated by institutional ownersOctober 6, 2023 | benzinga.comBiohaven Chief Financial Officer Trades Company's StockOctober 6, 2023 | msn.comBiohaven raises $258.7M from public offeringOctober 6, 2023 | finance.yahoo.comInsider Buying: CFO Matthew Buten Acquires 22,727 Shares of Biohaven Ltd (BHVN)October 6, 2023 | markets.businessinsider.comBiohaven Ltd. (BHVN) Gets a Buy from Piper SandlerOctober 3, 2023 | nasdaq.comBiohaven Prices Public Offering Of 10.23 Mln Shares At $22/shrOctober 3, 2023 | finance.yahoo.comHere's What Could Help Biohaven Ltd. (BHVN) Maintain Its Recent Price StrengthOctober 3, 2023 | finance.yahoo.comBiohaven Announces Pricing of $225 Million Public Offering of Common SharesOctober 2, 2023 | msn.comBiohaven proposes $200M stock offeringSeptember 27, 2023 | finance.yahoo.comBiohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%See More Headlines Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees928Year FoundedN/APrice Target and Rating Average Stock Price Target$29.17 High Stock Price Target$36.00 Low Stock Price Target$24.00 Potential Upside/Downside-12.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($7.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,280,000.00 Net MarginsN/A Pretax Margin-255.54% Return on Equity-110.06% Return on Assets-85.63% Debt Debt-to-Equity RatioN/A Current Ratio4.99 Quick Ratio4.99 Sales & Book Value Annual Sales$462.51 million Price / Sales5.81 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book4.24Miscellaneous Outstanding Shares80,230,000Free Float67,798,000Market Cap$2.69 billion OptionableOptionable Beta1.03 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Vladimir Coric M.D. (Age 52)Chairman & CEO Comp: $1.85MMr. Matthew Buten (Age 62)Chief Financial Officer Comp: $939.45kDr. Bruce D. Car DACVP (Age 61)Ph.D., Chief Scientific Officer Comp: $646.89kMs. Deb YoungDirector of Regulatory Affairs & OperationsMr. George C. Clark (Age 39)VP & Chief Accounting Officer Ms. Jennifer PorcelliVice President of Investor RelationsMr. Warren Volles J.D.General Counsel & Chief Legal OfficerMr. Clifford Bechtold M.S.Chief Compliance OfficerMs. Kimberly Gentile (Age 57)Senior Vice President of Clinical Operations Mr. John Tilton (Age 55)Chief Commercial Officer of Rare Diseases More ExecutivesKey CompetitorsZai LabNASDAQ:ZLABCorcept TherapeuticsNASDAQ:CORTAmphastar PharmaceuticalsNASDAQ:AMPHBausch Health CompaniesNYSE:BHCGalapagosNASDAQ:GLPGView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 72,673 shares on 12/6/2023Ownership: 0.183%American Century Companies Inc.Bought 60,689 shares on 11/30/2023Ownership: 0.636%Deutsche Bank AGBought 3,276 shares on 11/24/2023Ownership: 0.052%Graham Capital Management L.P.Bought 8,240 shares on 11/22/2023Ownership: 0.010%Walleye Capital LLCBought 3,400 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions BHVN Stock Analysis - Frequently Asked Questions Should I buy or sell Biohaven stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares. View BHVN analyst ratings or view top-rated stocks. What is Biohaven's stock price target for 2024? 5 analysts have issued 12-month price targets for Biohaven's stock. Their BHVN share price targets range from $24.00 to $36.00. On average, they expect the company's stock price to reach $29.17 in the next twelve months. This suggests that the stock has a possible downside of 12.3%. View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts. How have BHVN shares performed in 2023? Biohaven's stock was trading at $13.88 at the beginning of 2023. Since then, BHVN stock has increased by 139.6% and is now trading at $33.25. View the best growth stocks for 2023 here. Are investors shorting Biohaven? Biohaven saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 6,180,000 shares, a decrease of 8.0% from the October 31st total of 6,720,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.3 days. Approximately 10.5% of the company's shares are sold short. View Biohaven's Short Interest. When is Biohaven's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our BHVN earnings forecast. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) announced its earnings results on Tuesday, November, 14th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.33) by $0.17. What ETFs hold Biohaven's stock? ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT). When did Biohaven IPO? (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Biohaven's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (8.44%), FMR LLC (4.77%), Armistice Capital LLC (2.98%), Avidity Partners Management LP (1.88%), Adage Capital Partners GP L.L.C. (1.82%) and Northern Trust Corp (0.81%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John W Childs, Julia P Gregory, Matthew Buten and Vlad Coric. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:BHVN) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.